• Study Title: An Integrated Mammalian Library Approach for Optimization and Enhanced Microfluidics-Assisted Antibody Hit Discovery
• Authors: Ramona Gaa, Kavita Kumari, Hannah Melina Mayer, Desislava Yanakieva, Shang-Pu Tsai, Saurabh Joshi, Ralf Guenther & Achim Doerner (2023)
• Published In: Artificial Cells, Nanomedicine, and Biotechnology
• DOI: 10.1080/21691401.2023.2173219

• Higher Hit Rates with Microfluidics
  Researchers found that Cyto-Mine®’s microfluidic capabilities provide higher antibody integration rates while maintaining desired levels of monoclonality. The platform enables precise sorting, isolating specific antibody-secreting clones for rapid discovery.
• Enhanced Antibody Discovery Workflow
  The study’s authors highlight how the integration of Cyto-Mine® technology with mammalian secretion libraries enables accelerated screening. By using Sphere Fluidics’ advanced microfluidics, they could screen millions of functional antibody clones, reducing traditional bottlenecks in antibody discovery.
• Improving Therapeutic Antibody Quality
  Through the use of Cyto-Mine® technology, the research team achieved significant enrichment of relevant antibody clones, improving the likelihood of identifying high-quality therapeutic hits. This process effectively combines manufacturability, specificity, and functionality in a single streamlined workflow.

In this study, published in Artificial Cells, Nanomedicine, and Biotechnology, a team of scientists demonstrates how microfluidics-assisted hit discovery can be combined with mammalian libraries to advance antibody hit discovery, reduce attrition rates, and boost productivity in therapeutic antibody identification.

Learn how Cyto-Mine® supports leading-edge research in antibody discovery, enabling scientists to isolate the best candidates with precision and efficiency. Visit our Cyto-Mine® product page to explore the technology that is empowering today’s breakthroughs in biotherapeutics.